Chemotherapy in colorectal cancer: Recommendations from Norwegian gastrointestinal cancer group;Kjemoterapi ved kolorektalcancer: Anbefalinger fra Norsk gastrointestinal cancer gruppe

Tidsskrift for den Norske Laegeforening

Volumn 116, Issue 3, 1996, Pages 357-360

  Tveit, Kjell Magne ^a   Dahl, Olav ^b   Gerner, Tom ^c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c Kirurgisk Avdeling   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; FOLINATE CALCIUM; LEVAMISOLE; METHOTREXATE; SEMUSTINE; VINCRISTINE;

ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER REGRESSION; COLORECTAL CANCER; HUMAN; METASTASIS; QUALITY OF LIFE; REVIEW;

CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; HUMANS; NORWAY;

EID: 0030045667     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Engeland A, Haldorsen T, Tretli S, Hakulinen T, Hørte LG, Luostarinen T et al. Prediction of cancer incidence in the Nordic countries up to the years 2000 and 2010. Acta Pathol Microbiol Immunol Scand 1993; 101 (suppl 38): 34-41.
2. Buyse M, Zeleniuch-Jacquotte A, Chalmers TC. Adjuvant therapy of colorectal cancer: why we still don't know. JAMA 1988; 259: 3571-8.
3. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992; 6: 896-903.
4. Taylor I, Machin D, Mullee M, Trotter G, Cooke T, West C. A randomized controlled trial of adjuvant portal vein cytotoxic perfusion in colorectal cancer. Br J Surg 1985; 72: 359-62.
5. Fielding LP, Hittinger R, Grace RH, Fry JS. Randomized controlled trial of adjuvant chemotherapy by portal-vein perfusion after curative resection for colorectal adenocarcinoma Lancet 1992; 1: 502-6.
6. Arnaud JP, Buyse M, Adloff M, Nordlinger JC, Pector JC, Duez N. Interim analysis of a double-blind phase III clinical trial of adjuvant levamisole versus control in resectable Dukes' C colon cancer: a study of the EORTC Gastrointestinal Tract Cancer Cooperative Group. Recent Results Cancer Res 1988; 110: 101-3.
7. Sarker SK, Choudhary R, Subhas P, Vora LS, Banerjee AK. Follow-up study of adjuvant chemoimmunotherapy in colorectal carcinoma after definitive surgery. Indian J Cancer 1985; 22: 113-20.
8. Windle R, Bell PRF, Shaw D. Five year results of a randomized trial of adjuvant 5-fluorouracil and levamisole in colorectal cancer. Br J Surg 1987; 74: 569-72.
9. Laurie JA, Moertel CG, Fleming TR, Wieand HS, Leigh JE, Rubin J et al. Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. J Clin Oncol 1989; 7: 1447-56.
10. Moertel CG, Fleming TR, MacDonald JS, Haller DG, Laurie JA, Goodman PJ et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990; 322: 352-8.
11. NIH Consensus Conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990; 264: 1444-50.
12. Dahl O, Horn A, Morild I, Halvorsen JF, Odland G, Reinertsen S et al. Low-dose preoperative radiation postpones recurrences in operable rectal cancer: results of a randomized multicenter trial in western Norway. Cancer 1990; 66: 2286-94.
13. Påhlman L, Glimelius B. Pre- or postoperative radiotherapy in rectal and rectosigmoid carcinoma: report from a randomized multicenter trial. Ann Surg 1990; 211: 187-95.
14. Balslev IB, Pedersen M, Teglbjaerg PS. Postoperative radiotherapy in Dukes' B and C carcinoma of the rectum and rectosigmoid: a randomized multicenter study. Cancer 1986; 58: 22-8.
15. Gastrointestinal Tumor Study Group. Survival after postoperative combination treatment of rectal cancer. N Engl J Med 1986; 315: 1294-5.
16. Krook JE, Moertel CG, Gunderson LL, Wieand HS, Collins RT, Beart RW et al. Effective adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 1991; 324: 709-15
17. O'Connell MJ, Martenson JA, Wieand HS, Krook JE, Macdonald JS, Haller DG et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 1994; 331: 502-7.
18. MacFarlane JK, Ryall RDH, Heald RJ. Mesorectal excision for rectal cancer. Lancet 1993; 341: 457-60.
19. Fisher B, Wolmark N, Rockette H, Redmond C, Deutsch M, Wickerham DL et al. Postoperative chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. J Natl Cancer Inst 1988; 80: 21-9.
20. Minsky BD, Cohen, AM, Kemeny N, Enker WE, Kelsen DP, Reichman B et al. Enhancement of radiation-induced downstaging in rectal cancer by fluorouracil and high-dose leucovorin chemotherapy. J Clin Oncol 1992; 10: 79-84.
21. Moertel CG, Gunderson LL, Mailliard JA, McKenna PJ, Martenson JA jr., Burch PA et al. Early evaluation of combined fluorouracil and leucovorin as a radiation enhancer for locally unresectable, residual or recurrent gastrointestinal carcinoma. J Clin Oncol 1994; 12: 21-7.
22. Hughes KS, Simon R, Songhorabodi S, Adson MA, Ilstrup DM, Fortner JC et al. Resection of the liver for colorectal metastases: a multi-institutional study of indications for resection. Surgery 1988; 103: 278-88.
23. McAfee MK, Allen MS, Trastek VF, Ilstrup DM, Deschamps C, Pairolero PC. Colorectal lung metastases: results of surgical excision. Ann Thorac Surg 1992; 53: 780-6.
24. Begos DG, Ballantyne GH. Regional chemotherapy for colorectal liver metastases: thirty years without patient benefit. J Surg Oncol 1994; 56: 139-44.
25. Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Sequential methotrexate/5-fluorouracil/leucovorin (MFL) is superior to 5-fluorouracil atone in advanced symptomatic colorectal carcinoma: a randomized trial. J Clin Oncol 1989; 7: 1437-46.
26. Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. J Clin Oncol 1992; 10: 904-11.
27. Poon MA, O'Connell MJ, Moertel CG, Wieand HS, Cullinan SA, Everson LK et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989; 7: 1407-18.
28. Petrelli N, Douglass HO, Herrera L, Russell D, Stablein DM, Bruckner HW et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. J Clin Oncol 1989; 7: 1419-26.
29. Buroker TR, O'Connell MJ, Wieand HS, Krook JE, Gerstner JB, Maillard JA et al. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 1994; 12: 14-20.
30. Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Biochemical modulation of 5-fluorouracil: a randomized comparison of sequential methotrexate, 5-fluorouracil and leucovorin versus sequential 5-fluorouracil and leucovorin in patients with advanced symptomatic colorectal cancer. Ann Oncol 1993; 4: 235-41.
31. Scheithauer W, Rosen H, Kornek G-V, Sebesta C, Depisch D. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 1993; 306: 752-5.